Serum GDF15 as a potential biomarker for treatment response and survival in patients with resectable locally advanced gastric cancer undergoing neoadjuvant chemotherapy.
- 1Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 2Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
Background
Patients with locally advanced gastric cancer (LAGC) typically require neoadjuvant chemotherapy (NAC) to reduce tumor burden and improve surgical resectability. However, treatment responses to NAC vary substantially among individuals. This study investigated the potential value of baseline serum growth differentiation factor 15 (GDF15) for identifying patients at risk of poor treatment response and unfavorable survival outcomes among patients with LAGC receiving NAC.Methods
We retrospectively identified 318 eligible patients with LAGC who received NAC and enrolled 30 healthy controls. Serum GDF15 levels were measured by ELISA. In the unmatched cohort, the median baseline serum GDF15 concentration (2,147.3 pg/mL), determined before PSM, was used as a fixed cutoff to define the GDF15-L and GDF15-H groups (n = 159 each). After 1:1 PSM, 256 patients (n = 128 per group) were included in the matched analyses. Comparative analyses included baseline characteristics, CT images, preoperative endoscopic biopsy specimens and postoperative pathological features. Survival outcomes (OS and DFS) were assessed via Kaplan-Meier analysis. Multivariate Cox regression identified prognostic factors, and a prognostic nomogram was constructed.Results
High GDF15 expression correlated with advanced age (P = 0.045), poor tumor differentiation (P = 0.040), and elevated serum CA72-4 (P = 0.028). The GDF15-L group demonstrated superior median OS (58.1 vs. 54.0 months, P = 0.031) and DFS (47.1 vs. 26.9 months, P = 0.002) compared to GDF15-H counterparts. Preoperative endoscopic biopsy demonstrated a positive correlation between tissue GDF15 expression and serum GDF15 levels, while post-NAC imaging indicated greater tumor regression in the GDF15-L group. The GDF15-L group exhibited a higher pathological complete response (pCR) rate in postoperative pathological features (P < 0.001) while the GDF15-H group exhibited increased positive lymph nodes (P = 0.018) and a higher incidence of newly detected distant metastasis during or after NAC (P = 0.024). Multivariate analysis identified high GDF15 expression (P = 0.021) and high CAP degree (P = 0.022) as independent risk factors for OS, with younger age being protective (P = 0.016). Based on these factors, a prognostic nomogram was constructed to predict 1-year, 3-year, and 5-year OS and DFS.Conclusion
Low baseline serum GDF15 levels were associated with favorable radiological and pathological responses and prolonged survival in patients with LAGC receiving NAC. Baseline serum GDF15 may help identify patients at increased risk of poor response and unfavorable prognosis and may therefore serve as a potential biomarker for pretreatment risk stratification. However, because all patients received NAC, these findings do not establish that GDF15 predicts differential benefit from NAC, and prospective validation is required.
Related
- Iron homeostasis landscape informs patient survival and neoadjuvant chemotherapy response in cancer.
- Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
- Dickkopf-3 (DKK3) in cardiovascular diseases: from a stress-responsive biomarker to a potential therapeutic target
- Copper Ceruloplasmin as a Potential Biomarker of Biliary Tract Cancers: A Pilot Study
- Serum neuron-derived extracellular vesicle mitochondrial DNA as a potential biomarker for mild cognitive impairment due to AD
BibTeX
@article{cao2026serum,
title = {{Serum GDF15 as a potential biomarker for treatment response and survival in patients with resectable locally advanced gastric cancer undergoing neoadjuvant chemotherapy.}},
author = {Can Cao and Shunda Wang and Shikang Ding and Hongyun Huang and Tian Yu and Moxi Chen and Yibin Xie and Jianchun Yu},
journal = {Frontiers in molecular biosciences},
year = {2026},
month = oct,
doi = {10.3389/fmolb.2026.1948454},
url = {https://europepmc.org/article/MED/42908648},
note = {CC BY},
}
RIS
TY - JOUR
TI - Serum GDF15 as a potential biomarker for treatment response and survival in patients with resectable locally advanced gastric cancer undergoing neoadjuvant chemotherapy.
AU - Can Cao
AU - Shunda Wang
AU - Shikang Ding
AU - Hongyun Huang
AU - Tian Yu
AU - Moxi Chen
AU - Yibin Xie
AU - Jianchun Yu
PY - 2026
DA - 2026/10/07
JO - Frontiers in molecular biosciences
DO - 10.3389/fmolb.2026.1948454
UR - https://europepmc.org/article/MED/42908648
AB - Background Patients with locally advanced gastric cancer (LAGC) typically require neoadjuvant chemotherapy (NAC) to reduce tumor burden and improve surgical resectability. However, treatment responses to NAC vary substantially among individuals. This study investigated the potential value of baseline serum growth differentiation factor 15 (GDF15) for identifying patients at risk of poor treatment response and unfavorable survival outcomes among patients with LAGC receiving NAC.Methods We retrospectively identified 318 eligible patients with LAGC who received NAC and enrolled 30 healthy controls. Serum GDF15 levels were measured by ELISA. In the unmatched cohort, the median baseline serum GDF15 concentration (2,147.3 pg/mL), determined before PSM, was used as a fixed cutoff to define the GDF15-L and GDF15-H groups (n = 159 each). After 1:1 PSM, 256 patients (n = 128 per group) were included in the matched analyses. Comparative analyses included baseline characteristics, CT images, preoperative endoscopic biopsy specimens and postoperative pathological features. Survival outcomes (OS and DFS) were assessed via Kaplan-Meier analysis. Multivariate Cox regression identified prognostic factors, and a prognostic nomogram was constructed.Results High GDF15 expression correlated with advanced age (P = 0.045), poor tumor differentiation (P = 0.040), and elevated serum CA72-4 (P = 0.028). The GDF15-L group demonstrated superior median OS (58.1 vs. 54.0 months, P = 0.031) and DFS (47.1 vs. 26.9 months, P = 0.002) compared to GDF15-H counterparts. Preoperative endoscopic biopsy demonstrated a positive correlation between tissue GDF15 expression and serum GDF15 levels, while post-NAC imaging indicated greater tumor regression in the GDF15-L group. The GDF15-L group exhibited a higher pathological complete response (pCR) rate in postoperative pathological features (P < 0.001) while the GDF15-H group exhibited increased positive lymph nodes (P = 0.018) and a higher incidence of newly detected distant metastasis during or after NAC (P = 0.024). Multivariate analysis identified high GDF15 expression (P = 0.021) and high CAP degree (P = 0.022) as independent risk factors for OS, with younger age being protective (P = 0.016). Based on these factors, a prognostic nomogram was constructed to predict 1-year, 3-year, and 5-year OS and DFS.Conclusion Low baseline serum GDF15 levels were associated with favorable radiological and pathological responses and prolonged survival in patients with LAGC receiving NAC. Baseline serum GDF15 may help identify patients at increased risk of poor response and unfavorable prognosis and may therefore serve as a potential biomarker for pretreatment risk stratification. However, because all patients received NAC, these findings do not establish that GDF15 predicts differential benefit from NAC, and prospective validation is required.
SN - 2296-889X
ER -